Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation. Prosp...
Uloženo v:
| Vydáno v: | Journal of glaucoma Ročník 25; číslo 9; s. e807 |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.09.2016
|
| Témata: | |
| ISSN: | 1536-481X, 1536-481X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.
Prospective, double-masked, randomized, interventional study. Patients with XFS and OHT or XFG were enrolled. The study eyes were treated once daily with AR-12286, randomized to 0.5% or 0.7% for 24 weeks. Visits included baseline, 1, 4, and 12 weeks after drug initiation; at 12 weeks AR-12286 was discontinued for 1 week and was resumed at week 13. At the week 24 visit, AR-12286 was discontinued, and a final reexamination was performed at week 25.
Ten patients were treated. Mean baseline IOP was 25±2.4 mm Hg, mean IOP was reduced to 19.1±2.3 mm Hg at 1 week (P<0.001), 17.5±3.6 mm Hg at 4 weeks (P<0.001), and 17.4±3.6 mm Hg at 12 weeks (P<0.001), yielding an average IOP reduction of 23.6%, 30%, and 30.4%, respectively. At the week 13 visit, 1 week after the drug was discontinued, mean IOP increased to 21.6±5.4 mm Hg (P=0.06 compared with baseline visit). At week 24, the mean IOP was 21.8±7.8 mm Hg (P=0.2, and AR-12286 was discontinued). At week 25, the mean IOP was 21.3±5.3 mm Hg (P=0.06).
AR-12286 was well tolerated and provided statistically significant reduction in IOP in patients with XFS and OHT or XFG. This drug may represent an additional therapeutic paradigm for the treatment of XFG. |
|---|---|
| AbstractList | To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.
Prospective, double-masked, randomized, interventional study. Patients with XFS and OHT or XFG were enrolled. The study eyes were treated once daily with AR-12286, randomized to 0.5% or 0.7% for 24 weeks. Visits included baseline, 1, 4, and 12 weeks after drug initiation; at 12 weeks AR-12286 was discontinued for 1 week and was resumed at week 13. At the week 24 visit, AR-12286 was discontinued, and a final reexamination was performed at week 25.
Ten patients were treated. Mean baseline IOP was 25±2.4 mm Hg, mean IOP was reduced to 19.1±2.3 mm Hg at 1 week (P<0.001), 17.5±3.6 mm Hg at 4 weeks (P<0.001), and 17.4±3.6 mm Hg at 12 weeks (P<0.001), yielding an average IOP reduction of 23.6%, 30%, and 30.4%, respectively. At the week 13 visit, 1 week after the drug was discontinued, mean IOP increased to 21.6±5.4 mm Hg (P=0.06 compared with baseline visit). At week 24, the mean IOP was 21.8±7.8 mm Hg (P=0.2, and AR-12286 was discontinued). At week 25, the mean IOP was 21.3±5.3 mm Hg (P=0.06).
AR-12286 was well tolerated and provided statistically significant reduction in IOP in patients with XFS and OHT or XFG. This drug may represent an additional therapeutic paradigm for the treatment of XFG. To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.PURPOSETo evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and ocular hypertension (OHT) or exfoliative glaucoma (XFG) and examine any lasting effect on intraocular pressure (IOP) after discontinuation.Prospective, double-masked, randomized, interventional study. Patients with XFS and OHT or XFG were enrolled. The study eyes were treated once daily with AR-12286, randomized to 0.5% or 0.7% for 24 weeks. Visits included baseline, 1, 4, and 12 weeks after drug initiation; at 12 weeks AR-12286 was discontinued for 1 week and was resumed at week 13. At the week 24 visit, AR-12286 was discontinued, and a final reexamination was performed at week 25.METHODSProspective, double-masked, randomized, interventional study. Patients with XFS and OHT or XFG were enrolled. The study eyes were treated once daily with AR-12286, randomized to 0.5% or 0.7% for 24 weeks. Visits included baseline, 1, 4, and 12 weeks after drug initiation; at 12 weeks AR-12286 was discontinued for 1 week and was resumed at week 13. At the week 24 visit, AR-12286 was discontinued, and a final reexamination was performed at week 25.Ten patients were treated. Mean baseline IOP was 25±2.4 mm Hg, mean IOP was reduced to 19.1±2.3 mm Hg at 1 week (P<0.001), 17.5±3.6 mm Hg at 4 weeks (P<0.001), and 17.4±3.6 mm Hg at 12 weeks (P<0.001), yielding an average IOP reduction of 23.6%, 30%, and 30.4%, respectively. At the week 13 visit, 1 week after the drug was discontinued, mean IOP increased to 21.6±5.4 mm Hg (P=0.06 compared with baseline visit). At week 24, the mean IOP was 21.8±7.8 mm Hg (P=0.2, and AR-12286 was discontinued). At week 25, the mean IOP was 21.3±5.3 mm Hg (P=0.06).RESULTSTen patients were treated. Mean baseline IOP was 25±2.4 mm Hg, mean IOP was reduced to 19.1±2.3 mm Hg at 1 week (P<0.001), 17.5±3.6 mm Hg at 4 weeks (P<0.001), and 17.4±3.6 mm Hg at 12 weeks (P<0.001), yielding an average IOP reduction of 23.6%, 30%, and 30.4%, respectively. At the week 13 visit, 1 week after the drug was discontinued, mean IOP increased to 21.6±5.4 mm Hg (P=0.06 compared with baseline visit). At week 24, the mean IOP was 21.8±7.8 mm Hg (P=0.2, and AR-12286 was discontinued). At week 25, the mean IOP was 21.3±5.3 mm Hg (P=0.06).AR-12286 was well tolerated and provided statistically significant reduction in IOP in patients with XFS and OHT or XFG. This drug may represent an additional therapeutic paradigm for the treatment of XFG.CONCLUSIONSAR-12286 was well tolerated and provided statistically significant reduction in IOP in patients with XFS and OHT or XFG. This drug may represent an additional therapeutic paradigm for the treatment of XFG. |
| Author | Ritch, Robert Skaat, Alon Jasien, Jessica V |
| Author_xml | – sequence: 1 givenname: Alon surname: Skaat fullname: Skaat, Alon organization: Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York, NY †Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel – sequence: 2 givenname: Jessica V surname: Jasien fullname: Jasien, Jessica V – sequence: 3 givenname: Robert surname: Ritch fullname: Ritch, Robert |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27552517$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkN1KwzAAhYNM3I--gUguvenMT5uml2PMbTqYzInelSRNWKRNZtOCfQWf2ooTPDfncPg4F2cMBs47DcA1RlOMsvRu_bCcov9KED8DI5xQFsUcvw3-5SEYh_COEEGE4AswJGmSkASnI_C1MMYqoTroDdz7Y5_LsoOzorLOhkbXuoC7g48erRNBw7U7WGkbX8PZLsKEcAatg0-isdo1Ab7a5gAXn8aXtq-8g8-dK2pfaShcAbeqLUUNV91R14124Qfol5alaJWvxCU4N6IM-urkE_Byv9jPV9Fmu1zPZ5tI0YTxKKNaImkQRQJnhgkiRUF5xiRnGSWGEkEQTpWJDcOxIkhiyqQyhiSGx9QUZAJuf3ePtf9odWjyygaly1I47duQY45jxmOUJT16c0JbWekiP9a2EnWX__1HvgEa63Vp |
| CitedBy_id | crossref_primary_10_1007_s00417_019_04283_5 crossref_primary_10_1016_j_phrs_2020_105093 crossref_primary_10_1111_cbdd_13963 crossref_primary_10_1016_j_retram_2022_103343 crossref_primary_10_1007_s10384_018_0566_9 crossref_primary_10_1016_j_ophtha_2018_04_040 crossref_primary_10_1080_14656566_2017_1328498 crossref_primary_10_1089_jop_2019_0089 crossref_primary_10_1016_j_jcjo_2023_05_009 crossref_primary_10_1167_iovs_64_2_7 crossref_primary_10_3390_ijms22063279 crossref_primary_10_3390_molecules25194422 crossref_primary_10_1186_s12870_023_04341_5 crossref_primary_10_2147_JEP_S259297 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/IJG.0000000000000508 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1536-481X |
| ExternalDocumentID | 27552517 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .-D .Z2 0R~ 2V- 53G 5GY 5VS 8L- AAAAV AAHPQ AAIQE AARTV AASCR AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABVCZ ABXRP ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AENEX AFBFQ AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JK3 JK8 K8S KD2 KMI L-C N9A NPM N~M O9- OCUKA ODA OL1 OLG OLV OLZ OPUJH ORVUJ OUVQU OVD OVDNE OXXIT P-K P2P R58 RIG RLZ S4R S4S TEORI TSPGW V2I W3M WOQ WOW X3V X3W YFH ZB8 ZFV ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c3568-93eb0bf030a19f6a2bad3896b86932f32a2017cf4f614c20b136bcff25f843fd2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 17 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000384521100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1536-481X |
| IngestDate | Mon Sep 08 07:36:34 EDT 2025 Mon Jul 21 06:05:31 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3568-93eb0bf030a19f6a2bad3896b86932f32a2017cf4f614c20b136bcff25f843fd2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| PMID | 27552517 |
| PQID | 1814684095 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1814684095 pubmed_primary_27552517 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-September |
| PublicationDateYYYYMMDD | 2016-09-01 |
| PublicationDate_xml | – month: 09 year: 2016 text: 2016-September |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of glaucoma |
| PublicationTitleAlternate | J Glaucoma |
| PublicationYear | 2016 |
| SSID | ssj0020221 |
| Score | 2.250927 |
| Snippet | To evaluate the efficacy of rho-associated protein kinase inhibitor, AR-12286 topical solution, for its effect in eyes with exfoliation syndrome (XFS) and... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e807 |
| SubjectTerms | Administration, Topical Aged Aged, 80 and over Antihypertensive Agents - administration & dosage Dose-Response Relationship, Drug Double-Blind Method Exfoliation Syndrome - drug therapy Exfoliation Syndrome - physiopathology Female Follow-Up Studies Glaucoma - drug therapy Glaucoma - physiopathology Humans Intraocular Pressure - drug effects Isoquinolines - administration & dosage Male Middle Aged Ocular Hypertension - drug therapy Ocular Hypertension - physiopathology Ophthalmic Solutions - administration & dosage Prospective Studies rho-Associated Kinases - antagonists & inhibitors Treatment Outcome |
| Title | Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27552517 https://www.proquest.com/docview/1814684095 |
| Volume | 25 |
| WOSCitedRecordID | wos000384521100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bT4MwFG7UGeOL98u8pSa-kkGBAk9mMbsZN5c5lTfSFpqRLDDHZtxf8Fd7ykWfTEzkgSdoSs_p6XcufAehG1PYoRdypjk2s8BBYZ6mWNU0iyp0rNhN8tDFy4MzGLi-7w3LgFtWllVWNjE31GEqVIy8YahYlfJG7NvZm6a6RqnsatlCYx3VTIAySqsd_zuLAH49KflSqWa5hl_9Ouc5jd59p6AurC5bd38Hmflh09797zT30E4JM3Gz0It9tBYlB2irXybSD9FnS1FHMLHCqcTjdKZENV3hikpXNfDEo0mqmgvDMYd7ySTmsPfnuDnSDEJciuMEDwtO1gy_xosJbn3IdFoIGj-VPAiYJSF-zEtdcRc83nleLw8PwEidKVvCN7Ej9Nxuje-6WtmWQROmTcE8mhHXuQTrwAxPUkY4CwH2UO5SAIPSJAxAhSOkJeHoF0Tnhkm5kJLY0rVMGZJjtJGkSXSKMPg2jg4jOcQUlgCk5kkGkJAxAY4UIbyOrqtVDkDtVS6DJVG6zIKfda6jk0JUwazg5wiIY9uKie3sD2-fo22YLS2qxi5QTcKmjy7RpnhfxNn8KtcnuA-G_S_WXdMS |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Efficacy+of+Topically+Administered+Rho-Kinase+Inhibitor+AR-12286+in+Patients+With+Exfoliation+Syndrome+and+Ocular+Hypertension+or+Glaucoma&rft.jtitle=Journal+of+glaucoma&rft.au=Skaat%2C+Alon&rft.au=Jasien%2C+Jessica+V&rft.au=Ritch%2C+Robert&rft.date=2016-09-01&rft.eissn=1536-481X&rft.volume=25&rft.issue=9&rft.spage=e807&rft_id=info:doi/10.1097%2FIJG.0000000000000508&rft_id=info%3Apmid%2F27552517&rft_id=info%3Apmid%2F27552517&rft.externalDocID=27552517 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1536-481X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1536-481X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1536-481X&client=summon |